Jazz Pharmaceuticals plc (JAZZ) earnings date
Feb 24, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 36 days, typically, give or take 10 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Mon, Nov 2, 2026 | after close | 33 | 8-K |
| Q2 FY2026 | Mon, Aug 3, 2026 | after close | 34 | 8-K |
| Q1 FY2026 | Tue, May 5, 2026 | after close | 35 | 8-K |
| Q4 FY2025 | Tue, Feb 24, 2026 | after close | 55 | 8-K |
| Q3 FY2025 | Wed, Nov 5, 2025 | after close | 36 | 8-K |
| Q2 FY2025 | Tue, Aug 5, 2025 | after close | 36 | 8-K |
| Q1 FY2025 | Tue, May 6, 2025 | after close | 36 | 8-K |
| Q4 FY2024 | Tue, Feb 25, 2025 | after close | 56 | 8-K |
What they guided beta
| Q3 FY2026 | "Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results – Broad commercial execution drives record quarterly revenues of $1.2 billion (+10% YoY) – – Company raises full year 2026 total revenue guidance – – Ziihera ® launched in HER2+ 1L mGEA – – Xywav ® revenues grew 12% YoY with 425 net patient adds in 3Q26 – – Closed Actio acquisition, adding ABS-1230 (JZP6979) to rare epilepsy portfolio – DUBLIN, November 2, 2026 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2026 (3Q26)." exhibit |
| Q3 FY2026 | "Raised 2026 total revenue guidance to a range of $4.775 - $4.85 billion." exhibit Read from the sentence: revenue $4.775 billion to $4.85 billion, FY2026 |
| Q3 FY2026 | "Expect to present initial patient data at a medical meeting in 4Q26. 2 Capital Structure In the third quarter of 2026, the company completed a private placement of $1.25 billion aggregate principal amount of 1.875% exchangeable senior notes due 2032 (2032 notes)." exhibit |
| Q3 FY2026 | "Additionally, in the third quarter, the company amended and extended the company's Term Loan B, reducing the applicable margin by 50 basis points and extending the maturity by five years to May 2033, which is expected to generate cash interest savings and maintain cash reserves." exhibit |
| Q3 FY2026 | "For the nine months ended September 30, 2026, the company generated $1.3 billion of cash from operations reflecting strong business performance and continued financial discipline. 5 2026 Financial Guidance Jazz Pharmaceuticals has updated its full-year financial guidance, as shown in the table below, including raising its full-year 2026 revenue guidance, increasing its GAAP SG&A expense guidance to include restructuring expenses, and updating its effective tax rate guidance range to reflect the impact of the acquired IPR&D expense associated with the Actio acquisition." exhibit |
| Q2 FY2026 | "Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results – Continued commercial execution drives record total revenues of $1.2 billion (+16% YoY) – – Company raises 2026 revenue guidance – – Prepared to launch Ziihera ® in HER2+ 1L GEA immediately following FDA approval – – Xywav ® revenues grew 13% YoY with 525 net patient adds in 2Q26 – – Epidiolex ® revenues grew 16% YoY – DUBLIN, August 3, 2026 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2026 (2Q26) and raised revenue guidance for 2026." exhibit |
| Q2 FY2026 | ""Our second quarter results highlight strong execution and momentum across the business, delivering 16% year-over-year total revenue growth and driving a considerable increase to our full-year revenue guidance,” said Renee Gala, president and chief executive officer of Jazz Pharmaceuticals." exhibit |
| Q2 FY2026 | "Following strong 1H26 commercial execution, the company raised its 2026 revenue guidance range to $4.60 - $4.75 billion, reflecting anticipated double-digit YoY revenue growth from both Xywav and the combined epilepsy and oncology franchises. 1 Non-GAAP adjusted EPS is a non-GAAP financial measure." exhibit |
| Q2 FY2026 | "For the six months ended June 30, 2026, the company generated $824 million of cash from operations reflecting strong business performance and continued financial discipline. 2026 Financial Guidance Jazz Pharmaceuticals has updated its full-year 2026 financial guidance as shown in the table below." exhibit |
| Q2 FY2026 | "Guidance provided as of (In millions) August 3, 2026 May 5, 2026 Total Revenues $4,600 - $4,750 $4,250 - $4,500 GAAP: (In millions, except percentages) August 3, 2026 May 5, 2026 Gross margin % 89% - 90% 89% - 90% SG&A expenses $1,506 - $1,556 $1,424 - $1,497 R&D expenses $818 - $873 $811 - $867 Effective tax rate 0% - 10% 0% - 10% Weighted-average diluted shares outstanding 69 - 70 66 - 67 Non-GAAP adjusted: (In millions, except percentages) August 3, 2026 May 5, 2026 Gross margin % 90% - 91% 1 90% - 91% SG&A expenses $1,330 - $1,370 1 $1,260 - $1,320 R&D expenses $725 - $775 1 $725 - $775 Ef" exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/JAZZ
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/JAZZ
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/JAZZ/"><img src="https://veritasdata.dev/embed/JAZZ.svg" alt="JAZZ earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/JAZZ/)
Script
<script async src="https://veritasdata.dev/embed/JAZZ.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/JAZZ"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.